Oral semaglutide vs Orforglipron
The two GLP-1s you can swallow. One is a peptide with food and water rules, the other a small molecule with none — and their records are not the same size.
Oral semaglutide
Rybelsus, Wegovy pill
The first oral GLP-1 — approved for type-2 diabetes on the PIONEER program (as Rybelsus) and, since December 2025, for chronic weight management and cardiovascular risk reduction at a higher 25 mg dose (as the Wegovy pill).
Full Oral semaglutide evidence reviewOrforglipron
~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. FDA-approved for weight management (Foundayo, 2026) — the type-2 diabetes indication is still under review.
Full Orforglipron evidence reviewSide by side
| Oral semaglutide | Orforglipron | |
|---|---|---|
| Marketed for | Type-2 diabetes, weight loss | Weight loss, type-2 diabetes |
| Evidence grade | FDA-approved | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | FDA-approved | FDA-approved |
| How it's obtained | Rx product | Rx product |
| Key human source | PIONEER 1, JAMA 2019 | ATTAIN-1, NEJM 2025 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Both are FDA-approved, so the choice is about what each has actually proven. Oral semaglutide came through the PIONEER program for type-2 diabetes as Rybelsus and, since December 2025, is approved at 25 mg for chronic weight management and cardiovascular risk reduction as the Wegovy pill — the deeper record of the two. Orforglipron reported about 11% weight loss in ATTAIN-1 and was approved for weight management in 2026 as Foundayo, with its type-2 diabetes indication still under review; being a non-peptide small molecule, it carries no food or water timing rules. The two have not been compared head to head.
Oral semaglutide fits if
You want the oral GLP-1 with the longer record, including cardiovascular risk reduction, and the dosing rules are manageable for you.
Orforglipron fits if
The dosing rules are the obstacle, and a daily tablet with no food or water timing is worth a shallower evidence record.